Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion

Hayato Abe, Kenichi Mafune, Keisuke Minamimura, Masashi Abe, Akihisa Umemura, Tooru Mirata

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy and safety of bevacizumab (BV), combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinote-can (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) after resection of the primary lesion, have not been fully clarified. We examined clinical results of 35 patients on BV plus FOLFIRI at our hospital, and investigated the efficacy of BV plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens (26 patients were treated with BV at a dose of 5 mg/kg, 3 patients with BV 10mg/kg, and 6 patients had BV Increased from 5mg/kg to 10mg/kg). The average frequency of BV plus FOLFIRI treatment was 13. 9 times, and the average length of treatment was 10.0 months. The overall response rate was 17.1% (CR 1 patient, PR 5 patients, SD 21 patients, PD 8 patients). The median PFS was 11.0 months for FOLFIRI plus BV after first-line chemotherapy, and the median 05 was 23.0 months. The adverse events were 77.1% (>Grade 3, 55.5%) and the BV-associated adverse event was grade 3 hypertension (2 patients). The FOLFIRI plus BV regimen is an active and well-tolerated second-line chemotherapy treatment for patients with mCRC after resection of the primary lesion.

Original languageEnglish
Pages (from-to)601-604
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume40
Issue number5
Publication statusPublished - May 2013
Externally publishedYes

Keywords

  • FOLFIRI plus bevacizumab
  • Metastatic colorectal cancer
  • Second-line chemotherapy

Fingerprint

Dive into the research topics of 'Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion'. Together they form a unique fingerprint.

Cite this